HPB : the official journal of the International Hepato Pancreato Biliary Association · 2025
Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ishida Jun, Franklin Oskar, Franco Salvador R, Ishida Hiroyuki, Khomiak Andrii, Sugawara Toshitaka, Grandi Samuele, Stoop Thomas F, Kirsch Michael J, Schulick Richard D, Del Chiaro Marco
Аннотация
BACKGROUND: Chyle leak after pancreatic surgery is linked to malnutrition, but its impact on oncological outcomes is unclear. This study assessed if postoperative clinically relevant chyle leak (CR-chyle leak) affects adjuvant chemotherapy receipt rates and overall survival (OS) in pancreatic cancer patients.
METHODS: Patients who underwent resection for localized pancreatic ductal adenocarcinoma at the University of Colorado Hospital (2015-2023) were included. Year of surgery was divided in two time periods based on changes in dissection techniques, increased neoadjuvant therapies, and more surgeries for advanced disease in 2019. Risk factors for CR-chyle leak (grade B-C) and their relation to OS and adjuvant chemotherapy were analyzed using logistic and Cox regression models.
RESULTS: Among 487 patients, 93 (19.5 %) developed CR-chyle leak. Patients with CR-chyle leak more often had borderline/locally advanced disease, neoadjuvant chemotherapy, vascular resections, longer surgeries, and operated in 2019-2023. There were no differences in hospital stay (median 10 vs 10 days), adjuvant chemotherapy rates (70.5 % vs 70.2 %, p = 0.917), or median OS (28.5 vs 29.9 months, p = 0.477). CR-chyle leak was not associated with OS (HR 0.81; 95 % CI: 0.57-1.16) in the adjusted model.
CONCLUSION: CR-chyle leak is common after pancreatic cancer surgery but does not negatively impact oncological outcomes.
METHODS: Patients who underwent resection for localized pancreatic ductal adenocarcinoma at the University of Colorado Hospital (2015-2023) were included. Year of surgery was divided in two time periods based on changes in dissection techniques, increased neoadjuvant therapies, and more surgeries for advanced disease in 2019. Risk factors for CR-chyle leak (grade B-C) and their relation to OS and adjuvant chemotherapy were analyzed using logistic and Cox regression models.
RESULTS: Among 487 patients, 93 (19.5 %) developed CR-chyle leak. Patients with CR-chyle leak more often had borderline/locally advanced disease, neoadjuvant chemotherapy, vascular resections, longer surgeries, and operated in 2019-2023. There were no differences in hospital stay (median 10 vs 10 days), adjuvant chemotherapy rates (70.5 % vs 70.2 %, p = 0.917), or median OS (28.5 vs 29.9 months, p = 0.477). CR-chyle leak was not associated with OS (HR 0.81; 95 % CI: 0.57-1.16) in the adjusted model.
CONCLUSION: CR-chyle leak is common after pancreatic cancer surgery but does not negatively impact oncological outcomes.